Literature DB >> 16149907

Reversible mode of binding of serum proteins to DOTAP/cholesterol Lipoplexes: a possible explanation for intravenous lipofection efficiency.

Dmitri Simberg1, Aryeh Weiss, Yechezkel Barenholz.   

Abstract

There are many indications that interaction of serum proteins with intravenously injected cationic lipoplexes disturbs lipofection in vitro and in vivo. However, transfection with certain lipid compositions such as N-[1- (2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP)/cholesterol appears to be more resistant to serum and more efficacious. We investigated the mechanism of interaction between fluorescently labeled lipoplexes of the above composition and fluorescently labeled serum proteins. Fluorescence resonance energy transfer measurements in vitro indicate that serum proteins interact instantly and closely with the DOTAP/cholesterol lipoplexes. In accord with this, preinjection of fluorescently labeled serum into mice before injection of lipoplexes showed an immediate association of proteins with lipoplexes. Serum proteins colocalized with the lipoplexes in the lung vasculature; however, they dissociated from the cationic lipid as soon as 1 hr postinjection, probably because of displacement of serum proteins from lipoplexes by extracellular proteoglycans. Indeed, this displacement was imitated by heparin, a typical glycosaminoglycan, and could be explained by the inability of weakly acidic serum proteins to neutralize the DOTAP/cholesterol electrical surface potential psi0. The stability of the cationic lipid psi0 in serum could be a key reason for the high lung association and transfection efficiency with this formulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149907     DOI: 10.1089/hum.2005.16.1087

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  8 in total

1.  Transferrin-associated lipoplexes as gene delivery systems: relevance of mode of preparation and biophysical properties.

Authors:  Nuno Penacho; Ana Filipe; Sérgio Simões; Maria C Pedroso de Lima
Journal:  J Membr Biol       Date:  2008-02-21       Impact factor: 1.843

2.  Structural and formulation factors influencing pyridinium lipid-based gene transfer.

Authors:  Lin Zhu; Yan Lu; Duane D Miller; Ram I Mahato
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

3.  Somatostatin receptor type 2-based reporter expression after plasmid-based in vivo gene delivery to non-small cell lung cancer.

Authors:  Lin Han; Murali Ravoori; Guanglin Wu; Ryo Sakai; Shaoyu Yan; Sheela Singh; Kai Xu; Jack A Roth; Lin Ji; Vikas Kundra
Journal:  Mol Imaging       Date:  2013-10       Impact factor: 4.488

4.  Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-17

5.  Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans.

Authors:  Charles Lu; David J Stewart; J Jack Lee; Lin Ji; Rajagopal Ramesh; Gitanjali Jayachandran; Maria I Nunez; Ignacio I Wistuba; Jeremy J Erasmus; Marshall E Hicks; Elizabeth A Grimm; James M Reuben; Veerabhadran Baladandayuthapani; Nancy S Templeton; John D McMannis; Jack A Roth
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

6.  Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.

Authors:  Bingbing Dai; Shaoyu Yan; Humberto Lara-Guerra; Hiroyuki Kawashima; Ryo Sakai; Gitanjali Jayachandran; Mourad Majidi; Reza Mehran; Jing Wang; B Nebiyou Bekele; Veerabhadran Baladandayuthapani; Suk-Young Yoo; Ying Wang; Jun Ying; Feng Meng; Lin Ji; Jack A Roth
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

7.  Efficient delivery of plasmid DNA using cholesterol-based cationic lipids containing polyamines and ether linkages.

Authors:  Bieong-Kil Kim; Young-Bae Seu; Yun-Ui Bae; Tae-Won Kwak; Hyungu Kang; Ik-Jae Moon; Guen-Bae Hwang; So-Young Park; Kyung-Oh Doh
Journal:  Int J Mol Sci       Date:  2014-04-28       Impact factor: 5.923

8.  PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform.

Authors:  Shi-He Liu; Donald D Rao; John Nemunaitis; Neil Senzer; Guisheng Zhou; David Dawson; Marie-Claude Gingras; Zhaohui Wang; Richard Gibbs; Michael Norman; Nancy S Templeton; Francesco J Demayo; Bert O'Malley; Robbi Sanchez; William E Fisher; F Charles Brunicardi
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.